BACKGROUND: The single nucleotide polymorphism (SNP) Ser128Arg in the E-selectin gene is overrepresented in certain patient populations with atherosclerosis or restenosis. As this SNP enhances tissue factor-triggered coagulation in humans during systemic inflammation, we hypothesized that it may also predispose for the development of recurrent venous thromboembolism (VTE). METHODS: A total of 585 patients were prospectively observed after first VTE for recurrent, objectively documented, symptomatic VTE. Patients with secondary VTE, homozygous factor V Leiden, natural inhibitor deficiencies, lupus anticoagulant, or long-term anticoagulation therapy were excluded. The S128R SNP was genotyped by mutagenically separated polymerase chain reaction. RESULTS: A total of 102 patients (17%) were heterozygous, and 11 were homozygous (2%) for the Ser128Arg mutation. Ninety patients (15%) had recurrent VTE during follow-up. Homozygosity for the Ser128Arg SNP increased the cumulative likelihood, particularly for early recurrent VTE (log rank test, P<.05) and was an independent predictor of recurrent VTE (hazard ratio [HR], 4.1; 95% confidence interval [CI], 1.5-11.4) in a multivariate Cox regression model. In contrast, heterozygosity for the polymorphism was associated with an unaltered HR (HR, 1.1; 95% CI, 0.6-1.9) for recurrent VTE. CONCLUSIONS: Homozygosity for the S128R E-selectin allele appears to increase the risk for recurrent VTE several fold. If these findings are confirmed, this may represent a novel risk factor for recurrent VTE. These results also expand our knowledge on the association of this SNP with thrombotic disorders.
BACKGROUND: The single nucleotide polymorphism (SNP) Ser128Arg in the E-selectin gene is overrepresented in certain patient populations with atherosclerosis or restenosis. As this SNP enhances tissue factor-triggered coagulation in humans during systemic inflammation, we hypothesized that it may also predispose for the development of recurrent venous thromboembolism (VTE). METHODS: A total of 585 patients were prospectively observed after first VTE for recurrent, objectively documented, symptomatic VTE. Patients with secondary VTE, homozygous factor V Leiden, natural inhibitor deficiencies, lupus anticoagulant, or long-term anticoagulation therapy were excluded. The S128R SNP was genotyped by mutagenically separated polymerase chain reaction. RESULTS: A total of 102 patients (17%) were heterozygous, and 11 were homozygous (2%) for the Ser128Arg mutation. Ninety patients (15%) had recurrent VTE during follow-up. Homozygosity for the Ser128Arg SNP increased the cumulative likelihood, particularly for early recurrent VTE (log rank test, P<.05) and was an independent predictor of recurrent VTE (hazard ratio [HR], 4.1; 95% confidence interval [CI], 1.5-11.4) in a multivariate Cox regression model. In contrast, heterozygosity for the polymorphism was associated with an unaltered HR (HR, 1.1; 95% CI, 0.6-1.9) for recurrent VTE. CONCLUSIONS: Homozygosity for the S128RE-selectin allele appears to increase the risk for recurrent VTE several fold. If these findings are confirmed, this may represent a novel risk factor for recurrent VTE. These results also expand our knowledge on the association of this SNP with thrombotic disorders.
Authors: Roland C Preston; Said Rabbani; Florian P C Binder; Suzette Moes; John L Magnani; Beat Ernst Journal: Glycobiology Date: 2014-03-31 Impact factor: 4.313
Authors: Allan K Metz; Jose A Diaz; Andrea T Obi; Thomas W Wakefield; Daniel D Myers; Peter K Henke Journal: Methodist Debakey Cardiovasc J Date: 2018 Jul-Sep
Authors: Ian J Welsby; Mihai V Podgoreanu; Barbara Phillips-Bute; Richard Morris; Joseph P Mathew; Peter K Smith; Mark F Newman; Debra A Schwinn; Mark Stafford-Smith Journal: J Cardiothorac Vasc Anesth Date: 2010-01-06 Impact factor: 2.628
Authors: Linda M Polfus; Laura M Raffield; Marsha M Wheeler; Russell P Tracy; Leslie A Lange; Guillaume Lettre; Amanda Miller; Adolfo Correa; Russell P Bowler; Joshua C Bis; Shabnam Salimi; Nancy Swords Jenny; Nathan Pankratz; Biqi Wang; Michael H Preuss; Lisheng Zhou; Arden Moscati; Girish N Nadkarni; Ruth J F Loos; Xue Zhong; Bingshan Li; Jill M Johnsen; Deborah A Nickerson; Alex P Reiner; Paul L Auer Journal: Hum Mol Genet Date: 2019-02-01 Impact factor: 6.150
Authors: Daniel Myers; Patrick Lester; Reheman Adili; Angela Hawley; Laura Durham; Veronica Dunivant; Garrett Reynolds; Kiley Crego; Zoe Zimmerman; Suman Sood; Robert Sigler; William Fogler; John Magnani; Michael Holinstat; Thomas Wakefield Journal: J Vasc Surg Venous Lymphat Disord Date: 2020-03